Iron Chelation Enhances TAM and Triple Negative Breast Cancer Cell Death

Abstract

The goal of this study is preclinical testing of Deferiprone (DFP), an iron chelator in clinical use for non-oncologic diseases. The IC50 for tumor cells was lower than measured for macrophages (M0, M1, M2) indicating potential therapeutic gain and safety in treating cancer cells. In 4T1 tumors, we observed significantly smaller spleens in both size and weight in the DFP alone, cisplatin and paclitaxel groups treated with DFP. We found an increase in the spleen in percent of both CD4 effector T cells (CD4+ Foxp3-)and CD8 T cells and an increase in the ability of CD4 and CD8 T cells to make both IFNgamma or TNFalpha. In perfused 4T1 cells, we demonstrated metabolic inhibition of the tricarboxylic acid cycle in the MDA-231. WE have measured changes in oxygen consumption rate in 4T1 and MDA231 cells and macrophages and found changes in response to DFP.

Open PDF

Document Details

Document Type
Technical Report
Publication Date
Oct 01, 2020
Accession Number
AD1126320

Entities

People

  • Ronald Blasberg

Organizations

  • Sloan-Kettering Institute

Tags

Communities of Interest

  • Biomedical

DTIC Thesaurus Topics

  • Abstracts
  • Acquisition
  • Antineoplastic Agents
  • Biomedical Research
  • Breast Cancer
  • Cells
  • Chemistry
  • Chemotherapy
  • Culture Techniques
  • Cytokines
  • Frequency
  • Inhibition
  • Macrophages
  • Medical Personnel
  • Metabolism
  • Myeloid Cells
  • Neoplasms
  • Prostate Cancer
  • Proteins
  • Rate Of Consumption
  • Statistical Analysis
  • Therapy

Fields of Study

  • Medicine

Readers

  • Aerospace Engineering
  • Immunology
  • Oncology (Cancer Research).